Investor | Longitude Capital Partners II, LLC |
13D/G Filings
This page shows a list of all the recent 13D/G filings made by Longitude Capital Partners II, LLC . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).
When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.
Date | Form | Target | Prev Shares |
Current Shares |
Change (Percent) |
Ownership (Percent) |
Change (Percent) |
|
---|---|---|---|---|---|---|---|---|
2023-10-18 |
|
KALA / KALA BIO, Inc. | 108,239 | 108,239 | ||||
2023-08-18 |
|
RXST / RxSight, Inc. | 2,539,037 | 1,774,559 | ||||
2023-06-05 |
|
RXST / RxSight, Inc. | 2,506,972 | 2,539,037 | ||||
2023-03-16 |
|
APTX / Aptinyx Inc. | 3,644,551 | 192,805 | ||||
2023-02-14 |
|
KALA / KALA BIO, Inc. | 5,457,030 | 108,239 | ||||
2023-02-14 |
|
APTX / Aptinyx Inc. | 3,506,744 | 3,644,551 | ||||
2023-02-14 |
|
RPID / Rapid Micro Biosystems, Inc. | 4,192,547 | 4,189,845 | ||||
2023-01-03 |
|
VERO / Venus Concept Inc. | 3,691,349 | 3,466,118 | ||||
2022-02-15 |
|
RPID / Rapid Micro Biosystems, Inc. | 4,192,547 | 4,192,547 | ||||
2021-08-13 |
|
RXST / RxSight, Inc. | 2,506,972 | |||||
2021-02-12 |
|
PCVX / Vaxcyte, Inc. | 3,108,780 | |||||
2020-03-23 |
|
KALA / KALA BIO, Inc. | 2,895,366 | 5,457,030 | ||||
2020-02-12 |
|
0HBB / Aimmune Therapeutics Inc | 6,191,528 | 6,215,278 | ||||
2020-02-12 |
|
NBRV / Nabriva Therapeutics Plc | 4,012,375 | 4,256,527 | ||||
2020-02-12 |
|
APTX / Aptinyx Inc. | 3,190,079 | 3,506,744 | ||||
2019-11-18 |
|
VERO / Venus Concept Inc. | 3,691,349 | |||||
2019-02-12 |
|
0HBB / Aimmune Therapeutics Inc | 6,158,435 | 6,191,528 | ||||
2018-10-12 |
|
KALA / KALA BIO, Inc. | 2,278,506 | 2,895,366 | ||||
2018-08-07 |
|
NBRV / Nabriva Therapeutics Plc | 4,012,375 | |||||
2018-07-06 |
|
TCDA / Tricida Inc | 3,021,924 | |||||
2018-07-02 |
|
APTX / Aptinyx Inc. | 3,190,079 | |||||
2018-02-12 |
|
KALA / KALA BIO, Inc. | 2,278,506 | |||||
2018-02-12 |
|
0HBB / Aimmune Therapeutics Inc | 6,138,680 | 6,158,435 | ||||
2017-02-21 |
|
0HBB / Aimmune Therapeutics Inc | 6,138,680 | 6,138,680 | ||||
2017-02-10 |
|
0HBB / Aimmune Therapeutics Inc | 7,552,900 | 6,138,680 | ||||
2016-01-29 |
|
0HBB / Aimmune Therapeutics Inc | 7,552,900 |